Asia Pacific Non-Invasive Prenatal Testing Market Report by Component, Application, End User, Countries and Companies Analysis 2026-2034

Asia Pacific Non-Invasive Prenatal Testing Market Size and Forecast

Asia Pacific Non-Invasive Prenatal Testing (NIPT) Market is expected to expand significantly, increasing from US$ 1,603.85 million in 2025 to US$ 5,485.16 million by 2034. This growth is supported by rising awareness of prenatal genetic screening, increasing maternal age, and the growing adoption of advanced genomic technologies across developed and emerging countries. Improvements in healthcare infrastructure, greater accessibility to prenatal diagnostic services, and increasing preference for safe, accurate, and non-invasive screening solutions are further driving market expansion. The market is projected to grow at a CAGR of 14.64% from 2026 to 2034.

What is Non-Invasive Prenatal Testing and What Are Its Uses & Popularity Worldwide?

Non-Invasive Prenatal Testing (NIPT), also called cell-free DNA (cfDNA) screening, is a prenatal screening method that analyzes small fragments of placental DNA circulating in a pregnant woman’s blood. It can generally be performed from around 10 weeks of pregnancy and is primarily used to assess the risk of fetal chromosomal abnormalities, particularly Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13). It can also screen for certain sex-chromosome abnormalities, depending on the test.

NIPT has gained worldwide popularity because it requires only a maternal blood sample, avoiding the procedure-related risks associated with invasive diagnostic tests such as amniocentesis and chorionic-villus sampling. Its high screening performance has encouraged wider adoption, with the American College of Obstetricians and Gynecologists describing cfDNA as the most sensitive and specific screening test for common fetal aneuploidies. Increasing awareness of prenatal genetic conditions, delayed childbearing, improved genomic technologies, expanding diagnostic laboratories, and greater availability of specialized maternity services are supporting global adoption. However, NIPT remains a screening rather than diagnostic test, so positive results generally require confirmatory diagnostic testing.

What is Non-Invasive Prenatal Testing and Its Uses & Popularity in Asia Pacific

Non-Invasive Prenatal Testing (NIPT) is a blood-based prenatal screening method that analyzes cell-free fetal DNA circulating in a pregnant woman’s bloodstream to assess the risk of common chromosomal abnormalities, particularly trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). Unlike amniocentesis and chorionic villus sampling, NIPT does not require an invasive procedure and therefore avoids procedure-related risks associated with invasive diagnostic testing. Its popularity is increasing across Asia Pacific because of greater awareness of fetal genetic conditions, improvements in genomic sequencing, increasing availability of specialized diagnostic laboratories, and demand for safer prenatal screening.

China has emerged as a major adoption market; a large-scale publicly funded program in Hebei reported 93.3% NIPT coverage, involving more than 1.18 million pregnant women. In another Chinese study, 83.2% of high-risk pregnant women surveyed said they would opt for NIPT. India is also witnessing rising interest, although awareness and accessibility remain considerably lower than in leading Asian markets.

Non-Invasive Prenatal Testing National Screening Programs in the Top Asia-Pacific Countries

China – Province-Led Expansion of NIPT Screening

China does not currently operate a single, fully unified nationwide NIPT screening program. Instead, implementation has developed through provincial and local maternal-health systems, with substantial adoption in major regions such as Beijing, Shanghai, and Guangdong. NIPT is increasingly incorporated into prenatal screening services, particularly in urban hospitals and among pregnancies requiring additional chromosomal-abnormality assessment. A large-scale Chinese program involving 1,185,416 pregnant women achieved 93.3% NIPT coverage, demonstrating the country’s capacity for population-level implementation. The program also reported a 97.4% reduction in the need for prenatal diagnosis compared with maternal serum screening.  However, access, reimbursement, and availability remain different across provinces, contributing to an urban-rural divide. Continued investment in maternal healthcare infrastructure and genomic testing is expected to strengthen NIPT integration across China.

Australia – Established National Prenatal Screening Framework

Australia has a well-developed prenatal screening pathway in which NIPT is available as an optional screening test, generally from 10 weeks of pregnancy. It is offered alongside conventional screening approaches, including first-trimester screening and ultrasound. NIPT is not universally funded through Medicare, meaning patients may need to pay out of pocket depending on the provider and circumstances. The Australian healthcare system emphasizes informed choice, pre-test counseling, and appropriate follow-up diagnostic testing following high-risk results. The structured healthcare environment, established pathology networks, and relatively high awareness of prenatal genetic testing support NIPT adoption. However, out-of-pocket costs can create differences in access. Australia’s model therefore combines broad availability with patient choice rather than universal government-funded NIPT screening.

Japan – Certified Institution-Based Controlled Screening Model

Japan does not operate universal government-funded NIPT screening for the general pregnant population. Instead, NIPT has traditionally been provided through certified medical institutions, with strong emphasis on genetic counseling and appropriate clinical management. Japan’s Ministry of Health reported that 92 NIPT facilities were certified under the country’s established implementation system as of December 2022, with plans to expand the network.  NIPT has particularly been offered to women with increased risk of fetal chromosomal abnormalities, including advanced maternal age and relevant medical or pregnancy history. The Japanese model places considerable emphasis on ethical considerations, informed consent, genetic counseling, and confirmatory diagnostic testing. This controlled approach supports responsible use of NIPT while limiting the possibility of treating a screening result as a definitive diagnosis.

Singapore – Government-Guided Prenatal Screening Integration

Singapore has a structured prenatal screening system supported by its advanced public and private healthcare infrastructure. NIPT is available as an additional screening option for pregnant women, generally following clinical assessment and counseling. The country’s healthcare model emphasizes early identification of chromosomal abnormalities, informed decision-making, and access to specialist care. NIPT is not universally provided free of charge, and patients may incur out-of-pocket expenses depending on the selected test and provider. Singapore’s relatively small population and concentrated healthcare infrastructure allow prenatal diagnostic services to be delivered through well-established hospitals and specialist centers. Government-supported maternal healthcare services and strong laboratory capabilities provide favorable conditions for NIPT adoption. Nevertheless, NIPT remains a screening technology rather than a definitive diagnostic test, meaning high-risk results require appropriate confirmatory testing such as amniocentesis or chorionic villus sampling.

India – Private-Sector-Led and Emerging NIPT Adoption

India currently does not have a universal national NIPT screening program. NIPT is primarily provided through private diagnostic laboratories, tertiary-care hospitals, fertility centers, and specialist prenatal clinics, particularly in major metropolitan areas. Awareness and adoption are increasing, but access remains uneven because of testing costs, limited insurance coverage, shortages of specialized facilities, and differences in healthcare infrastructure between urban and rural areas. An Indian study involving 200 pregnant women found that only 14 participants (7%) had prior knowledge of NIPT, highlighting the considerable awareness gap. Healthcare professionals were the primary source of prenatal-screening information for 170 of the 200 participants.  India’s large birth cohort and expanding private healthcare sector provide substantial long-term potential for NIPT. However, broader adoption will depend on greater public awareness, improved affordability, expanded genetic counseling, and wider availability of advanced prenatal diagnostic services.

Growth Drivers of the Asia Pacific Non-Invasive Prenatal Testing Market

Increasing Adoption of Advanced Genomic and Sequencing Technologies

Rapid advances in next-generation sequencing (NGS), bioinformatics, cell-free DNA analysis, and molecular diagnostics are strengthening the accuracy, scalability, and availability of NIPT across Asia Pacific. These technologies enable laboratories to identify fetal chromosomal abnormalities from a maternal blood sample without requiring invasive fetal sampling. China demonstrates the potential of large-scale implementation: a recent study of 1,185,416 pregnant women in Hebei reported NIPT coverage of 93.3% and found that the program reduced the need for prenatal diagnosis by 97.4% compared with maternal serum screening, while also reporting better cost-effectiveness. Earlier research involving 189,809 NIPT samples from 28 provincial-level administrative regions in China reported combined sensitivity of 99.1% and specificity of 99.9% for trisomies 21, 18, and 13. Such evidence is increasing physician confidence in NIPT and encouraging diagnostic laboratories to expand their testing capabilities. As sequencing costs decline and genomic infrastructure improves in China, India, Japan, South Korea, Australia, and Southeast Asia, NIPT is expected to become increasingly integrated into prenatal screening pathways.

Rising Maternal Age and Growing Need for Chromosomal Abnormality Screening

Increasing maternal age is an important structural driver for the Asia Pacific NIPT market because the probability of fetal chromosomal abnormalities, particularly trisomy 21, rises with advancing maternal age. As more women postpone childbirth because of education, careers, urbanization, and changing family structures, demand for reliable prenatal genetic screening is increasing. Evidence from China’s large-scale NIPT program found that parental age of 35 years or older was associated with a 4.31-fold higher risk of fetal trisomy 21 compared with non-advanced parental age. Another Chinese study involving 189,809 NIPT samples found that the observed risk of trisomies 21 and 18 increased significantly among women aged 39 years and older. NIPT is particularly attractive for older expectant mothers because it provides early screening through a maternal blood sample rather than an invasive procedure. Growing awareness among obstetricians and pregnant women about age-related genetic risks is therefore supporting wider adoption across developed and emerging Asia Pacific economies.

Expanding Prenatal Healthcare Infrastructure and Awareness

Improvements in maternal healthcare infrastructure, diagnostic laboratories, specialist hospitals, genetic counseling, and private healthcare services are increasing access to advanced prenatal screening throughout Asia Pacific. The region represents a particularly large potential patient population: approximately 57.5 million of the 134 million global births recorded in 2023 occurred in the Asia Pacific region, accounting for more than 43% of births worldwide. China has expanded prenatal screening infrastructure considerably; government information reported that by the end of 2018, more than 1,000 institutions provided prenatal screening services and 371 institutions provided prenatal diagnostic services. Awareness is also improving among expectant mothers, although it varies significantly by country and socioeconomic group. In a Chinese survey, 83.2% of high-risk pregnant women expressed willingness to undergo NIPT. India is developing as another growth market, with market estimates indicating strong expansion as healthcare infrastructure, awareness, and private diagnostic services improve.

Challenges of the Asia Pacific Non-Invasive Prenatal Testing Market

High Testing Costs and Unequal Access

The relatively high cost of NIPT compared with conventional prenatal screening remains a major barrier to widespread adoption across several Asia Pacific countries. Although the test requires only a maternal blood sample, sophisticated sequencing platforms, laboratory infrastructure, bioinformatics, quality control, and specialist interpretation can increase testing costs. This creates a significant affordability gap between higher-income urban populations and lower-income or rural communities. Evidence from China demonstrates the direct relationship between cost and adoption. In one study, only 1.6% of women with local household registration underwent NIPT when invasive testing was available free of charge, compared with 20.6% among women without local household registration, who had to pay for invasive testing; reducing the price of NIPT subsequently increased uptake among the latter group. India’s situation illustrates another accessibility challenge. A study of pregnant women found that only 14 of 200 participants (7%) had knowledge of NIPT, while another prenatal-screening study reported that only 6 participants had previously undergone NIPT. Consequently, affordability, insurance coverage, and unequal geographic availability can restrict market penetration.

Limited Awareness, Regulatory Complexity, and Need for Confirmatory Diagnosis

Despite technological progress, NIPT remains a screening test rather than a definitive diagnostic test, creating a need for appropriate counseling and, when results indicate high risk, confirmatory diagnostic procedures such as amniocentesis or chorionic villus sampling. Differences in clinical guidelines, regulatory frameworks, reimbursement policies, and genetic-testing infrastructure across Asia Pacific can complicate market development. China’s experience illustrates this complexity: national guidance has positioned NIPT as a secondary screening method between conventional serum screening and invasive prenatal diagnosis, while the government has considered factors including medical risk, ethics, privacy, human genetic-resource protection, biosafety, and price. Awareness also remains uneven. In an Indian study, participants were much more familiar with ultrasound and conventional double/triple tests than with NIPT, and healthcare workers were the primary information source for 170 of 200 participants. In addition, a Chinese survey found strong willingness to use NIPT but noted limited knowledge and understanding among expectant mothers. These gaps can slow responsible adoption and require greater investment in physician education, genetic counseling, public awareness, and standardized testing pathways.

Non-Invasive Prenatal Testing Product Launches Worldwide

• Natera – Fetal Focus™ (2025): Natera launched Fetal Focus in August 2025 as a single-gene NIPT for inherited conditions. The initial test analyzed five genes associated with cystic fibrosis, spinal muscular atrophy, alpha-thalassemia, and beta-hemoglobinopathies.
• Natera – Fetal Focus™ 21-Gene NIPT (2026): In January 2026, Natera expanded Fetal Focus to 21 genes, broadening screening for inherited disorders. The expanded test demonstrated 96% overall sensitivity and 98% population-weighted specificity in the reported clinical dataset.
• Natera – Fetal RhD NIPT (2024): Natera launched a cell-free DNA-based fetal RhD test in May 2024. The test can determine fetal RhD status from maternal blood at nine weeks of pregnancy and reported 100% sensitivity and more than 99% specificity in its validation study.
• Yourgene Health – IONA® Care+ (2025): Yourgene Health launched IONA Care+ in February 2025 as a comprehensive NIPT service covering genetic conditions, including microdeletions. Results are designed to be delivered within 3–5 working days through participating laboratories and clinics.
• Yourgene Health – IONA® NIPT Workflow in Morocco (2023): Yourgene installed its IONA NIPT workflow at Centre de Biologie Riad in Morocco in November 2023, enabling local prenatal testing and reducing reliance on invasive testing.
• Yourgene Health – MagBench® Automated DNA Extraction Instrument (2023): In September 2023, Yourgene launched MagBench and its associated kit for automated DNA extraction in NIPT workflows, supporting laboratory automation and processing efficiency.
• BGI Genomics – NIFTY® Pro: BGI Genomics’ NIFTY Pro uses low-depth whole-genome sequencing and bioinformatics to screen for trisomies 21, 18, and 13. The test can also assess additional autosomal and sex-chromosome aneuploidies and 92 types of chromosomal deletions/duplications.
• Natera – Panorama® NIPT: Panorama is Natera’s SNP-based NIPT, launched originally in 2013 and subsequently expanded to screen for common chromosomal abnormalities, sex-chromosome abnormalities, triploidy, and selected microdeletion syndromes.
• Illumina – VeriSeq™ NIPT Solution: Illumina’s VeriSeq NIPT platform is a sequencing-based prenatal screening solution designed to analyze cell-free DNA for common fetal chromosomal abnormalities. VeriSeq 2 is among the broader NIPT solutions used for expanded genomic screening.
• ARCEDI – EVITA TEST COMPLETE: ARCEDI developed a fetal-cell-based NIPT using fetal cells isolated from maternal blood. Its EVITA TEST COMPLETE is designed for testing at 10–14 weeks of gestation and uses whole-genome sequencing to assess aneuploidies and genome-wide copy-number variations.

Rising Adoption of Advanced Genomic Instruments in Aisa Pacific

Asia Pacific Non-Invasive Prenatal Testing (NIPT) Instruments Market is expanding as diagnostic laboratories increasingly adopt advanced technologies for accurate prenatal screening. NIPT instruments include next-generation sequencing (NGS) platforms, automated nucleic-acid extraction systems, PCR instruments, and bioinformatics solutions used to analyze fetal cell-free DNA from maternal blood. China has demonstrated the potential for large-scale NIPT implementation, with a recent program covering more than 1.18 million pregnant women and achieving 93.3% NIPT coverage. Increasing investment in healthcare infrastructure across China, Japan, India, South Korea, and Australia is encouraging diagnostic laboratories to upgrade sequencing and molecular-testing capabilities. China’s prenatal-screening network included more than 1,000 prenatal-screening institutions and 371 prenatal-diagnostic institutions by the end of 2018.  High-throughput instruments can improve laboratory productivity, shorten processing times, and support larger testing volumes. The expansion of private diagnostic networks and growing emphasis on precision medicine are further encouraging adoption. As NIPT becomes increasingly incorporated into maternal healthcare, demand for automated, scalable, and cost-efficient instruments is expected to increase throughout Asia Pacific.

Increasing Demand for Prenatal Genetic Screening in Asia Pacific

Asia Pacific Non-Invasive Prenatal Testing (NIPT) Services Market is experiencing strong growth as expectant parents and healthcare professionals increasingly seek safe and accurate prenatal screening. NIPT services analyze cell-free fetal DNA from maternal blood to assess the risk of chromosomal abnormalities, particularly trisomy 21, trisomy 18, and trisomy 13. A large Chinese study involving 189,809 NIPT samples reported approximately 99.1% sensitivity and 99.9% specificity for the three major trisomies, supporting confidence in NIPT as a screening technology. The availability of NIPT services is increasing through hospitals, fertility centers, specialist prenatal clinics, and private diagnostic laboratories across China, India, Japan, South Korea, and Australia. In China, a recent large-scale program demonstrated 93.3% coverage among more than 1.18 million pregnant women, highlighting the potential for NIPT services to become integrated into routine prenatal screening.  Rising maternal age, greater healthcare expenditure, improved genetic counseling, and growing awareness of chromosomal disorders are supporting demand. However, differences in reimbursement, testing costs, and healthcare accessibility remain important challenges. Continued expansion of diagnostic networks and improved affordability are expected to make NIPT services increasingly accessible across the region.

Growing Focus on Trisomy 21 Screening in Asia Pacific

Asia Pacific Down Syndrome Non-Invasive Prenatal Testing Market is expanding as Down syndrome, or trisomy 21, remains one of the primary chromosomal abnormalities targeted by NIPT. The technology analyzes fetal cell-free DNA in maternal blood, providing a non-invasive approach to identifying pregnancies at increased risk. In a large Chinese study of 189,809 NIPT samples, trisomy 21 detection demonstrated approximately 99.1% sensitivity, illustrating the strong screening performance of NIPT. Increasing maternal and parental age is an important factor supporting demand for trisomy 21 screening. A recent Chinese NIPT program involving more than 1.18 million pregnant women found that parental age of 35 years or older was associated with a 4.31-fold higher risk of fetal trisomy 21 compared with younger parental age.  Growing awareness among expectant parents, particularly in urban areas, is encouraging greater use of NIPT. Nevertheless, high testing costs, differences in healthcare access, and limited awareness in rural communities can restrict adoption. Expansion of genetic counseling, public awareness programs, and affordable screening services is expected to strengthen the market across Asia Pacific.

Hospitals Strengthen NIPT Adoption in Asia Pacific

Asia Pacific Non-Invasive Prenatal Testing (NIPT) Hospitals Market is expanding as hospitals increasingly incorporate genetic screening into maternal healthcare. Hospitals play a central role in patient counseling, blood-sample collection, laboratory coordination, interpretation of results, and referral for confirmatory diagnostic testing. The growing demand for early detection of chromosomal abnormalities is encouraging public and private hospitals across China, Japan, India, South Korea, and Australia to strengthen prenatal diagnostic capabilities. The region’s expanding healthcare infrastructure is creating favorable conditions for hospital-based NIPT. China’s healthcare system had more than 1,000 institutions providing prenatal screening services and 371 institutions providing prenatal diagnostic services by the end of 2018.  More recently, a large-scale Chinese program demonstrated that NIPT could achieve 93.3% coverage among over 1.18 million pregnant women, indicating substantial potential for integration into healthcare systems.  Partnerships between hospitals and specialized genetic-testing companies are also improving access to advanced testing. However, high equipment and testing costs, shortages of trained specialists, and unequal availability of advanced diagnostic services in rural areas remain constraints. Continued healthcare modernization and greater emphasis on preventive maternal care should support hospital-based NIPT adoption across Asia Pacific.

Rising Awareness of Advanced Prenatal Screening in India

India Non-Invasive Prenatal Testing (NIPT) Market is expanding as awareness of genetic screening and maternal-fetal healthcare improves. NIPT provides a non-invasive method of screening for chromosomal abnormalities, particularly trisomy 21, trisomy 18, and trisomy 13, using cell-free fetal DNA from a maternal blood sample. However, awareness remains uneven. An Indian study found that only 14 of 200 pregnant women (7%) surveyed had prior knowledge of NIPT, highlighting significant room for education and market development. Expansion of private hospitals, fertility centers, and specialized diagnostic laboratories is improving access to NIPT, particularly in major metropolitan areas. Healthcare professionals are also an important source of information, with 170 of 200 participants in the cited Indian study identifying healthcare workers as their primary source of prenatal-screening information.  Despite this progress, relatively high testing costs, limited insurance reimbursement, uneven laboratory infrastructure, and restricted access in rural and semi-urban areas continue to constrain adoption. Ethical considerations and cultural sensitivities surrounding prenatal genetic testing can also influence patient decisions. Nevertheless, improvements in maternal healthcare infrastructure, growing genomic-testing capabilities, and increasing demand for early and safer prenatal screening are expected to support long-term NIPT market development in India.

Large-Scale Adoption Drives Market Expansion in China

China Non-Invasive Prenatal Testing (NIPT) Market is experiencing strong growth as genomic technologies become increasingly integrated into prenatal healthcare. NIPT is widely used to screen for major chromosomal abnormalities, including Down syndrome, trisomy 18, and trisomy 13. Evidence from a large-scale Chinese program involving 1,185,416 pregnant women demonstrates the country’s substantial adoption potential, with NIPT coverage reaching 93.3%. The program also reported a 97.4% reduction in the need for prenatal diagnosis compared with maternal serum screening. China’s expanding diagnostic infrastructure and technological capabilities are strengthening NIPT adoption. A study covering 189,809 NIPT samples from 28 provincial-level regions reported approximately 99.1% sensitivity and 99.9% specificity for trisomies 21, 18, and 13.  Government healthcare infrastructure has also expanded, with more than 1,000 institutions providing prenatal screening services and 371 institutions providing prenatal diagnostic services reported by the end of 2018.  Nevertheless, differences in healthcare access between urban and rural areas, testing costs, and the availability of specialist genetic services remain challenges. Continued investment in genomic infrastructure, broader screening programs, and competition among domestic and international testing providers should support further NIPT penetration across China.

Growing Preference for Safe Genetic Screening in Japan

Japan Non-Invasive Prenatal Testing (NIPT) Market is developing steadily as expectant parents and healthcare professionals increasingly seek accurate and non-invasive methods for prenatal chromosomal screening. NIPT primarily assesses the risk of trisomy 21, trisomy 18, and trisomy 13 through analysis of cell-free fetal DNA in maternal blood. Its non-invasive nature makes it an attractive screening option, particularly for pregnancies associated with increased chromosomal-abnormality risk. Japan’s sophisticated healthcare infrastructure, advanced genetic-testing capabilities, and established specialist medical centers provide favorable conditions for NIPT adoption. The country has also established formal frameworks governing NIPT implementation and genetic counseling. In 2023, Japan’s Ministry of Health, Labour and Welfare reported that the Japan Society of Obstetrics and Gynecology had expanded its NIPT implementation system, with 92 certified NIPT facilities as of December 2022 and plans to expand the system further. Increasing maternal age is an important factor supporting demand for prenatal chromosomal screening, while the concentration of specialized testing centers in major urban areas creates opportunities for further expansion. At the same time, relatively high testing costs, limited availability of specialized facilities in some regions, and the need for professional genetic counseling can restrict adoption. Continued expansion of certified facilities, improvements in testing accessibility, and greater awareness of prenatal genetic screening are expected to strengthen the Japanese NIPT market over the long term.

Market Segmentation

Component

• Instruments
• Kits and Reagents
• Services

Application

• Down Syndrome (Trisomy 21)
• Edwards Syndrome (Trisomy 18)
• Patau Syndrome (Trisomy 13)
• Turner Syndrome
• Other Applications

End User

• Hospitals
• Diagnostic Labs

Countries

• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand
• Rest of Asia Pacific

All the Key players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Eurofins Scientific
• F. Hoffmann-La Roche Ltd
• Invitae Corporation
• Illumina Inc.
• Natera Inc.
• Centogene NV
• Qiagen

Report Details: